title: Express approval of immune checkpoint inhibitors: a conflict between science and finance.
authors.affiliation: Oncology Department, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Hampig Raphael
authors.initials: HR
authors.lastname: Kourie
authors.affiliation: Medical Oncology Department, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
authors.forename: Samer
authors.initials: S
authors.lastname: Tabchi
authors.affiliation: Hematology-Oncology Department, Faculty of medicine, Saint Joseph University, Beirut, Lebanon.
authors.forename: Joseph
authors.initials: J
authors.lastname: Kattan
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D007167:Immunotherapy / Q000191:economics* / Q000331:legislation & jurisprudence
chemical_list: D000970:Antineoplastic Agents
keywords: approval; challenge; checkpoint inhibitors; conflict; economy; express; finance; healthcare; immunotherapy; science